Janowicz, Z.A.

hbsag vaccine anti-hb binding hansenula-derived variant serum hepatitis serum anti-hbs adw 2 hepatitis b vaccine ayw 3 hansenula-derived hbsag response sample antibody hansenula-derived hbsag /adw antigen level iu /l phase result reference heijtink vaccination genhevacb hbsag /adr hbsag /ayw hb-vax-dna hansenula-derived hbsag /adr engerix-b vaccinee difference hepavax-gene hb-vax polymorpha study hansenula-derived hbsags yeast fluence infection heterologou amount van bergen p hepatitis b vaccines dna-derived vaccines immunogenicity anti-hbs level reference anti-hbs variant speci fic reference serum 2191–2196 vaccine anti-hbs plasma-derived hbsag /adw antigenic ef ficacy 100 iu /l hansenula-derived hbsag binding subtype inhibition group ayw 2 variant type disease preparation ”-determinant hansenula protection experiment assay immunisation room temperature vaccination group product fi eld reference preparation polymorpha hbsag hansenula polymorpha netherland